STOCK TITAN

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.

Positive
  • Chairman Gabriele Cerrone increased his stake in the company by purchasing 24,500 shares, a sign of confidence in ACUT's future.
  • Total shares held by Cerrone now stand at 3,855,723, indicating strong insider commitment.
Negative
  • None.

LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.

Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: jeff@accustem.com

Investor Contact:
Wendy Blosser
Email: investors@accustem.com


FAQ

What recent stock purchase did AccuStem Chairman Gabriele Cerrone make?

Gabriele Cerrone purchased an additional 24,500 shares of AccuStem, increasing his total holdings to 3,855,723 shares.

What is the stock symbol for AccuStem Sciences?

The stock symbol for AccuStem Sciences is ACUT.

What is the focus of AccuStem Sciences?

AccuStem Sciences is focused on developing innovative molecular testing for cancer diagnostics to improve patient outcomes.

When did AccuStem Sciences announce the stock purchase by its Chairman?

The stock purchase by Chairman Gabriele Cerrone was announced on November 22, 2022.

ACCUSTEM SCIENCES INC

OTC:ACUT

ACUT Rankings

ACUT Latest News

ACUT Stock Data

5.85M
6.17M
45.66%
Biotechnology
Healthcare
Link
United States of America
New York